ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1242

Sex Differences in Treatment Response to Three Different Biological Treatments and Corticosteroids in Patients with Early Rheumatoid Arthritis

Kristina Lend1, Ronald F van Vollenhoven2, Jon Lampa3, Merete Hetland4, Espen Haavardsholm5, Dan Nordström6, Michael Nurmohamed7, Bjorn Gudbjornsson8, Anna Rudin9, Mikkel Ostergaard10, Till Uhlig11, Gerdur Grondal8, Kim Hørslev-Petersen12, Marte S Heiberg5, Tuulikki Sokka-Isler13, Jos Twisk14 and Irene van der Horst-Bruinsma15, 1Department of Medicine, Rheumatology Unit, The Karolinska Institute, Stockholm, Sweden, 2Amsterdam University Medical Centers, Department of Rheumatology and Clinical Immunology, Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, 3Karolinska University Hospital, Department of Medicine, Rheumatology Unit, The Karolinska Institute, Stockholm, Sweden, Stockholm, Sweden, 4DANBIO and COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, 5Diakonhjemmet Hospital, Oslo, Norway, 6Division of Internal Medicine and Rheumatology, Helsinki University Hospital, Helsinki, Finland, 7Amsterdam University Medical Centers, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, 8Landspitali University Hospital, University of Iceland, Reykjavik, Iceland, 9Rheumatology Clinic, Sahlgrenska University Hospital, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden, 10Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Glostrup, Denmark, 11Diakonhjemmet Hospital, University of Oslo, Oslo, Norway, 12Danish Hospital for Rheumatic Diseases, University of Southern Denmark, Reykjavik, Iceland, Haderslev, Denmark, 13University of Eastern Finland, Jyväskylä Central Hospital, Jyväskylä, Finland, 14Department of Epidemiology and Biostatistics, Amsterdam University Medical Centres, Amsterdam, Netherlands, 15Department of Rheumatology, VU University Medical Centre, Amsterdam, Netherlands

Meeting: ACR Convergence 2021

Keywords: Abatacept, corticosteroids, rheumatoid arthritis, Tocilizumab

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 8, 2021

Session Title: RA – Treatments Poster II: PROs, Biomarkers, & Systemic Inflammation (1223–1256)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: To investigate sex differences in clinical response to three different biological treatments in combination with methotrexate (MTX) versus MTX plus corticosteroids (active conventional treatment; ACT), in early RA. We hypothesized that men and women differ in their response to one or several treatments.

Methods: DMARD-naïve patients with symptom duration < 2 years, moderate to severe disease activity (DAS28-CRP >3.2) and RF or ACPA positivity, or increased CRP (≥10 mg/L) were randomized in the phase IV NORD-STAR trial (NCT01491815) on 1:1:1:1 ratio, stratified by country, sex and ACPA status to 1)ACT; 2)certolizumab pegol (CPZ); 3)abatacept (ABA); 4)tocilizumab (TCZ)1. Remission outcomes were analyzed with longitudinal logistic generalized estimating equations analysis. The model included treatment, time (4, 8, 12, 16, and 24 weeks) and sex. The primary and secondary clinical results of the trial after 24 weeks have been published1. For this sub-study, the co-primary outcomes were differences in clinical disease activity index remission (CDAI≤2.8) over 24 weeks and at 24 weeks with ACT as the reference. Sex differences were assessed by interaction terms (males vs. females within each treatment comparison).

Results: This study included all 812 patients in the NORD-STAR trial (251 men and 561 women). The mean age was 56.5 (SD 14.0) and 53.2 (SD 15.0) years in males and females, respectively. Corresponding baseline DAS28-CRP was 5.0 (SD 1.0) and 5.0 (SD 1.1) and CDAI 27.5 (SD 11.6) and 28.1 (SD 12.0).
The crude CDAI remission rates at 24 weeks were 55.0% in males and 50.0% in females for ACT, 57.1% and 52.4% for CZP, 65.0% and 51.1% for ABA and 61.1% and 39.6% for TCZ (Figure 1). The analyses were adjusted for the stratification variables, age, BMI and DAS28-CRP at baseline. Using ACT as the reference, the adjusted overall odds ratios (OR) for achieving CDAI remission (95% confidence intervals, CI) with CZP were 1.26 (0.73-2.19) and 1.26 (0.88-1.81) in males and females, respectively, with ABA 1.25 (0.74-2.13) and 0.86 (0.60-1.24) and with TCZ 1.70 (1.01-2.87) and 0.76 (0.51-1.13). Corresponding odds ratios at 24 weeks with CZP were 1.41 (0.62-3.18) and 1.12 (0.66-1.89), with ABA 2.19 (0.96-4.97) and 1.04 (0.62-1.73) and with TCZ 1.54 (0.68-3.49) and 0.66 (0.38-1.14). For the primary and several secondary outcomes, women responded significantly poorer than men to TCZ compared with ACT (Table 1).
The percentage of males and females who experienced at least one adverse event with ACT was 85.7% and 86.1%, respectively, with CZP 82.5% and 82.7%, with ABA 70.3% and 84.3% and with TCZ 93.2% and 96.0%. The percentage of men and women who stopped treatment early with ACT was 6.3% and 11.1%, respectively, with CZP 12.5% and 10.8%, with ABA 6.3% and 5.0% and with TCZ 6.8% and 14.0%.

Conclusion: After 24 weeks, higher remission rates were observed in men than in women for all four treatment arms, suggesting that this generalized sex difference is related to the disease itself rather than to the treatments. In contrast, a distinctly lower treatment response was seen in female patients treated with tocilizumab versus conventional treatment, suggesting a sex-effect that is specific for IL-6 blockade.

References
1.Hetland et al. BMJ 2020; 371:m4328


Disclosures: K. Lend, None; R. van Vollenhoven, Bristol-Myers Squibb, 2, 5, 6, GlaxoSmithKline, 2, 5, 6, Eli Lilly, 5, Pfizer, 2, 5, 6, Roche, 5, UCB, 2, 5, 6, AbbVie, 2, 6, AstraZeneca, 2, 6, Biogen, 2, 6, Biotest,, 2, 6, Galapagos, 2, 6, Gilead, 2, 6, Janssen, 2, 6, Sanofi, 2, 6, Servier, 2, 6, Velabio, 2, 6, BMS, 5, GSK, 5, Celgene, 2, 6; J. Lampa, None; M. Hetland, Biogen, 2, 5, 6, Celltrion, 2, 6, Janssen Biologics B.V, 2, 6, MSD, 2, 6, Pfizer, 2, 5, 6, Samsung Bioepis, 2, 6, AbbVie, 5, BMS, 5, Eli Lilly Denmark A/S, 5, 12, personal fees, Lundbeck Fond, 5, Roche, 5, Sandoz, 5, Novartis, 5, Merck, 5, Orion Pharma, 12, personal fees, Medac, 6; E. Haavardsholm, Pfizer, 6, AbbVie, 2, 6, Celgene, 2, Janssen, 2, Gilead, 2, Eli-Lilly, 2, UCB, 2, 6, Novartis, 12, personal fees; D. Nordström, Abbvie, 6, BMS, 6, Lilly, 6, MSD, 6, Novartis, 6, Pfizer, 6, Roche, 6, UCB, 6, Celgene, 5; M. Nurmohamed, BMS, 5, Abbvie, 5, Celltrion, 12, personal fees, MSD, 5, Pfizer, 5, Amgen, 5, Eli Lilly, 12, personal fees; B. Gudbjornsson, Novartis Healthcare, 2, Amgen, 6; A. Rudin, AstraZeneca, 12, financial support; M. Ostergaard, AbbVie, 2, 5, 6, Bristol-Myers Squibb, 2, 6, Celgene, 2, 6, Novartis, 2, 5, 6, Boehringer Ingelheim, 2, 6, Eli Lilly, 2, 6, Hospira, 2, 6, Janssen, 2, 6, Merck, 2, 5, 6, Novo, 2, 6, Orion, 2, 6, Pfizer Inc, 2, 6, Regeneron, 2, 6, Roche, 2, 6, UCB, 2, 6, GSK, 2, 6, Mundipharma, 2, 6, Schering-Plough, 2, 6, Takeda, 2, 6, Wyeth, 2, 6, Centocor, 2, 5, 6; T. Uhlig, None; G. Grondal, None; K. Hørslev-Petersen, None; M. Heiberg, Roche, 6; T. Sokka-Isler, AbbVie, 2, Amgen, 2, BMS, 2, Celgene, 2, DiaGraphIT, 2, Medac, 2, MSD, 2, Novartis Healthcare, 2, Orionpharma, 2, Pfizer, 2, Roche, 2, Sandoz, 2, UCB, 2; J. Twisk, None; I. van der Horst-Bruinsma, None.

To cite this abstract in AMA style:

Lend K, van Vollenhoven R, Lampa J, Hetland M, Haavardsholm E, Nordström D, Nurmohamed M, Gudbjornsson B, Rudin A, Ostergaard M, Uhlig T, Grondal G, Hørslev-Petersen K, Heiberg M, Sokka-Isler T, Twisk J, van der Horst-Bruinsma I. Sex Differences in Treatment Response to Three Different Biological Treatments and Corticosteroids in Patients with Early Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/sex-differences-in-treatment-response-to-three-different-biological-treatments-and-corticosteroids-in-patients-with-early-rheumatoid-arthritis/. Accessed January 31, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sex-differences-in-treatment-response-to-three-different-biological-treatments-and-corticosteroids-in-patients-with-early-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences